In-111 DTPA-octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18 FDG positron emission tomography and extensive conventional radiographic imaging

What Was Tested

Researchers studied Octreotide in this clinical trial publication.

The utility of In-111 DTPA octreotide scintigraphy (SRS) for disease detection in patients with metastatic thyroid carcinoma (TCA) remains controversial.

The authors compared the sensitivity of In-111-based SRS, F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET), and extensive conventional radiographic imaging (CRI) in this type of cancer.

Who Took Part

The abstract describes 21 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

SRS, FDG PET, and CRI were performed concurrently in 21 patients (age, 56.4 +/- 12.9 years) who had aggressive TCA.

How the Study Was Run

Concordance rates % of lesion positivity among pairs of different techniques (A and B) were calculated as the ratio of the number of lesions positive with both techniques divided by the sum of the total number of lesions positive with technique A + total number of lesions positive with technique B, which was then multiplied by 200.

What Was Measured

Topics PubMed links to this paper include Bone Neoplasms, Carcinoma, Cohort Studies, Fluorodeoxyglucose F18, Head and Neck Neoplasms, Lung Neoplasms and Lymphatic Metastasis.

What This Means in Plain Language

This is a clinical trial of Octreotide in 21 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2003 (Clinical nuclear medicine), a journal based in United States.

More context: the Octreotide compound page, all human trials.